MSB 3.21% $1.13 mesoblast limited

Ann: Update on BLA for Graft Versus Host Disease, page-35

  1. 2,071 Posts.
    lightbulb Created with Sketch. 99
    I don't understand and can't believe I am actually posting after some of the immediate nothing posts that have come out.

    But, in what universe does that announcement state that the FDA have rejected Remestemcel-L... they simply asked (whilst unbelievable that they are after that 9 to 1 decision) to again prove efficacy. The product works, we all know this. We just have to wait a little while longer for it to prove itself again.

    I'll be topping up again.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.